Search for stocks /

Vikram Thermo Q3 FY26: 44% OPM, ₹11 Cr PAT, 35% ROCE – Smallcap Excipient King or Quiet Compounding Machine?


1. At a Glance – The Silent Margin Monster

At ₹148 per share and a market cap of ₹463 Cr, Vikram Thermo (India) Ltd is not shouting on TV business channels — but its numbers are whispering something interesting. Q3 FY26 sales stood at ₹34 Cr, PAT at ₹11 Cr, and operating margins at a spicy 44%. That’s not typo territory. That’s “pharma polymer printing money” territory.

Stock P/E sits at 13.6 versus industry median around 16.9. ROCE is 35.5%, debt-to-equity just 0.02, and interest coverage 95 times. Translation? Bankers probably call them for loans, not the other way around.

But wait — revenue growth is flat (Q3 sales down 0.87% YoY), and 3-month returns are -15.4%. So Mr. Market isn’t throwing confetti.

Is this a boring compounder hiding in plain sight? Or just a temporary margin spike story?

Let’s peel this polymer onion.


2. Introduction – Pharma’s Invisible Ingredient Maker

You’ve heard of pharma companies. You’ve heard of APIs. But have you heard of excipients?

No? Good. That’s why Vikram Thermo exists.

Founded in 1985, the company manufactures pharmaceutical excipients — the silent ingredients that help drugs dissolve, sustain release, mask taste, and behave properly inside your body.

Without excipients, your tablet is just a bitter powder. With them, it becomes a time-controlled, stomach-safe miracle pill.

The company is ISO 9001 certified, GMP compliant, EXCiPACT certified — which basically means it doesn’t cook chemicals in a backyard drum.

In May 2024, Vikram Thermo and Vikram Aroma got demerged after NCLT sanction. So structurally, it has streamlined operations.

And now Q3 FY26 shows 44% operating margins.

Forty-four percent.

In chemicals.

Pause and absorb that.

But here’s the catch — sales growth is not explosive. So is this a high-margin niche or peak-cycle sugar rush?

Let’s decode.


3. Business Model – WTF Do They Even Do?

Vikram Thermo manufactures:

Pharma Polymers

Used in drug release systems — sustained, extended, modified, controlled, targeted. Basically, they control when and how the drug dissolves.

Cosmetic Polymers

Thickening agents for creams, gels, and lotions. That silky feel? That’s polymer science.

Ion Exchange Polymers

Used for taste masking and suspension formulations.

Imagine trying to swallow a bitter antibiotic syrup without taste masking. Exactly.

Brands:

  • Drug Coat – Enteric coating, film coating, sustained release
  • DRCoat – Aqueous & non-aqueous coating systems
  • AquaPol – Acrylate polymers
  • Apion – For API disintegration & taste masking

Two production facilities in Gujarat:

  • Unit 1: ~6000 TPA
  • Unit 2: ~4000 TPA

So roughly 10,000 TPA capacity.

Revenue breakup FY25:

  • 99% Sale of Finished Goods
  • 1% Other operating revenue

Clean. No fancy financial income games.

Now question: When margins are 40%+, are we looking at pricing power or temporary chemical cycle benefits?

Let’s open the books.


4. Financials Overview – The Quarter That Sparkled

Quarterly Results – Figures in ₹ Crores

EPS:

  • Jun 2025: ₹2.53
  • Sep 2025: ₹3.53
  • Dec 2025: ₹3.49

Average = (2.53 + 3.53 + 3.49) / 3 = ₹3.18 approx

Annualised EPS = ₹3.18 × 4 = ₹12.72

Current Price ₹148
Recalculated P/E = 148 / 12.72 ≈ 11.6

Lower than displayed 13.6. Interesting.

Quarterly Comparison Table

MetricLatest Qtr (Dec 2025)YoY Qtr (Dec 2024)Prev Qtr (Sep 2025)YoY %QoQ %
Revenue₹34 Cr₹34 Cr₹35 Cr0%-2.9%
EBITDA₹15 Cr₹13 Cr₹15 Cr15%0%
PAT₹11 Cr₹9 Cr₹11 Cr22%0%
EPS₹3.49₹2.87₹3.5321.6%-1.1%

Commentary?

Revenue flat. Profit up.

That means margins expanded.

OPM moved from 39% to 44%.

This is either:

  1. Operational efficiency
  2. Raw material softening
  3. Product mix shift
  4. Or management unlocked polymer cheat code

But sales stagnation is visible. So growth investors might yawn.


5. Valuation Discussion – Fair Value Range

Method 1: P/E Based

Annualised EPS ≈ ₹12.72

Industry median P/E ≈ 16.9
Current P/E ≈ 11.6

If valued at:

  • 14× → ₹178
  • 16× → ₹203
  • 18× → ₹229

Method 2: EV/EBITDA

TTM EBITDA ≈ ₹49 Cr
Enterprise Value ≈ ₹461 Cr

EV/EBITDA = 9.13

If sector trades at 11–13×:

Implied EV range:
₹539 Cr – ₹637 Cr

After adjusting net cash (low debt), implied equity range roughly ₹540–₹640 Cr
Per share range ≈ ₹170 – ₹200+

Method 3: Simple DCF (Conservative)

Assume:
Growth 8–10%
Margin stable
Discount rate 12%

Fair value band roughly aligns ₹170–₹210 zone.

Fair Value Range: ₹170 – ₹220

This fair value range is for educational purposes only and is not investment advice.


6. What’s Cooking – News & Drama

May 2024: Demerger sanctioned by NCLT. That cleans structural complexity.

FY25 Capex:
₹7 Cr on PPE and intangibles
CWIP ₹24 lakh
Commitments ₹38 Cr (advances ₹37 Cr)

₹38 Cr commitment vs ₹463 Cr market

Join 10,000+ investors who read this every week.
Become a member
error: Content is protected !!